Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Toba... ( Cooperation with Kentucky Bioproce...)

Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants

Date:9/29/2008

Cooperation with Kentucky Bioprocessing for future-oriented technology

LEVERKUSEN, Germany and OWENSBORO, Ky., Sept. 29 /PRNewswire/ -- Bayer Innovation GmbH and Kentucky Bioprocessing, LLC (KBP) are collaborating to develop a facility at KBP's Owensboro plant in the US state of Kentucky for the production service of biopharmaceuticals. Based on Bayer's proprietary magnICON(R) technology, plant made pharmaceutical proteins (PMP) and other high-value products will be produced in tobacco plants on commercial scale.

Under terms of the agreement, KBP will adapt its existing cGMP (cGMP = current Good Manufacturing Practice) compliant facility by installing an automated system for high throughput transfection of tobacco host plants. The agreement makes KBP the "preferred production partner" for the application of magnICON(R), an innovative technology for the fast high-yield production of proteins in tobacco plants.

Bayer has internal product development projects - for example a vaccine for the therapy of Non-Hodgkin-Lymphoma - based on the magnICON(R) platform. Beyond that Bayer is also in the process of licensing out this technology to several parties. "To accelerate these applications of this technology, we decided to team up with an experienced external manufacturer, and KBP, with its excellent facilities and highly qualified personnel is the best choice in our view," said Dr. Detlef Wollweber, General Manager of Bayer Innovation.

"Bayer and its subsidiary, Bayer Innovation, are among the highest regarded participants in the PMP sector," said KBP Chairman Hugh Haydon. "Our association with them is not only important for the growth of KBP, but we believe is also significant in the evolution and development of the PMP industry in Owensboro and worldwide."

Construction on the magnICON(R) related improvements at KBP is scheduled to begin in October 2008. Completion and initial testing of the new facilities is planned for spring of 2
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
2. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
3. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
4. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
5. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
6. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
7. Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
8. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
9. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
10. Bayer CropSciences Vegetable Seed Business Nunhems Acquires US Lettuce Seed Company Paragon Seed
11. ImmunoVaccine Technologies Broadens Its Patent Protection to Japan

Post Your Comments:

Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Toba...( Cooperation with Kentucky Bioproce...)